Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Wednesday, October 14, 2026

Back to today

October 2026 Random Ramblings

October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI premiums for Oura and home builders.

CMG $38B
Yet Another Value Podcast 81 clicks

From X

@BrokenMoats 3 clicks

Broken Moats on X

Quickly back to very attractive levels to put back on short exposure on the software sector after the manic move in Q3 and digestion in September before the sudden crash up in the past 10 days..... AI wins software is in trouble - faster disruption more competition, pricing pressure AI trade is over, software is going to catch down as the market will tank and this won't sit that out (the are not cheap) Disruption and pricing is the tailwind, now valuation is too. Rates don't hurt either as up until recently these were considered long duration assets Recent results were status quo for most (no real acceleration) and pitch AI cohort growth as growing xx% but its not uplifting the total growth they are just changing what they charge for to show the street what it wants to hear) -- that phase is over, valuations are in many cases at year and multi year highs. SBC still a problem. Now comes renewals in the back of this year and thats where the issues will start to emerge on retention and pricing. An thats day 1 they will snowball overtime for the vast majority of these companies. Plenty of names to choose from: $PAYC $DOCU $TEAM $DDOG $PCTY $GDDY $RNG
@ParadisLabs 3 clicks

Paradis on X

An example that there are always trades in the market. $NAVN +12% in a ~couple weeks while sentiment & flows for semis/bottlenecks has fallen off. If anyone wants a Navan investment thesis: Navan is a corporate travel and expense platform. I believed that the market punished the stock (-22%) after Q2 earnings for no good reason. Plus, I also heard some pretty big investors bought the dip aggressively. It makes sense to follow the flows sometimes when fundamentals align. - Total GBV rose 45% to >$3B driven by new customers, ramping cohorts, and expansion of installed base. - Enterprise customers: Continued momentum in the enterprise market. - AI platform adoption: Over 50% of AI calls now run on Navan's proprietary models, with its AI support agent handling about 60% of customer interactions. Ultimately, investors were disappointed because they reported rising op. costs and expanded op. losses. But the market completely overlooked the fact that corporate traven demand has skyrocketed w/ business travel in the US generating $624B in GDP (Global Business Travel Association). Going forwards, I believe that enterprises will look for AI-native solutions that save them time and money while also resulting in better outcomes for the customer. From what I hear, Navan's AI is pretty sweet. ***I have taken profits to bolster my cash piles. Also, $IOT is flat over the same period.
@stockgutter 2 clicks

SG on X

I asked @grok to assess how the full results that $MRNA plans to release at ESMO that would strengthen or weaken the impression from top line results announced in August. The results are copied below. Seems reasonable to me at first glance (without having checked any of the data cited) -- anyone have a different view? ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ Items that could weaken (or further strengthen) the positive view include: - Magnitude of benefit: Hazard ratios (HRs), confidence intervals, absolute risk reductions, and landmark rates (e.g., 1- or 2-year RFS/DMFS). The earlier Phase 2b KEYNOTE-942 showed an RFS HR of ~0.51 (~49% relative risk reduction) and a DMFS HR of ~0.41 at 5 years. A substantially weaker Phase 3 effect (for example, HR closer to 0.75–0.85 with modest absolute benefit) could make the result look less compelling given the complexity, cost, and personalized manufacturing of the therapy. A comparable or stronger effect would reinforce the topline. - Statistical robustness and maturity: Width of confidence intervals, exact p-values, number of events, and median follow-up duration. Narrow intervals and a solid number of events support reliability; wide intervals, low event counts, or very short follow-up at the interim analysis could raise questions about reproducibility or durability. Subgroup consistency: Results by stage (IIB/IIC vs. III vs. IV), age, BRAF status, PD-L1 expression, geography, or other factors. Benefit concentrated in higher-risk stages or selected subgroups would narrow the practical population and commercial opportunity relative to a broadly consistent effect. Durability (Kaplan–Meier curves): Early separation that later plateaus or converges would suggest limited long-term impact. Sustained separation would support durability. - Overall survival signal: Any immature OS HR, death counts, or curve separation. An adverse or flat trend (while not decisive this early) could temper enthusiasm pending mature data. - Safety, tolerability, and feasibility details: Grade ≥3 adverse events, serious AEs, immune-related AEs, discontinuations, quality-of-life/patient-reported outcomes, and any manufacturing metrics (production success rate, turnaround time, or treatment delays). Higher toxicity, discontinuations, or practical barriers could offset efficacy gains. The topline noted consistency with prior experience and no new signals, but granular rates matter. - Stronger, consistent, durable efficacy with manageable safety and feasible delivery would solidify the positive assessment, support regulatory filings, and underpin commercial expectations. Marginal magnitude, inconsistency across key subgroups, limited durability, or meaningful safety/feasibility issues would lead to a more cautious view of clinical utility and value, even though the trial formally met its endpoints.
@BrokenMoats 6 clicks

Broken Moats on X

$BSP really have to question Gregg as the right to choice to lead Berkshire with this BSP investment. While it's meaningless in size to Berkshire, it's what it says about the investment process under Gregg and how they are underwriting managers. This does not strike me as a Buffet investment on any level. Something to watch as he continues to deploy capital....not sure how you get comfortable with an acquisition roll up of intangible assets, especially against the unknown of ai disruption. They should go back and study the intangible asset roll ups from the prior decade in the pharma space

Investor Letters

All letters

Lennar, Part One: The Story

Lennar grew from a Miami builder into one of America’s two largest homebuilders, controlling land largely through options and land banks…

LEN $17B
Latticework by MOI Global 10 clicks

Lennar, Part Two: The Deep Dive

Lennar’s second audio program examines the homebuilder’s business for professional investors and housing analysts.

LEN $17B
Latticework by MOI Global 11 clicks

Insider activity September 2026

Asian insider buying rose 19% to US$2.4 billion across 930 September transactions, led by Grab CEO Anthony Tan’s US$30 million purchase…

GRAB $12B
Asian Century Stocks 6 clicks

Vicor Update, Part Two

Vicor uses ITC exclusion-order cases to license power-module patents, with published royalty multipliers rising from 1.0x before filing to…

VICR $12B
CV's Substack 3 clicks

Expert Call | Nebius

Nebius’s 1 GW annual active-capacity target from 2027 is realistic, according to a former product manager, with greenfield data centers…

NBIS $56B
P Equity Research 4 clicks

The Week That Was

Treasury yields surged as the Fed’s expected hike shifted to December, while Micron beat guidance and forecast $61.5 billion in quarterly…

JBL $31B
CV's Substack

Nike, Part Two: The Deep Dive

Nike’s second Latticework program examines the company and the global athletic footwear and apparel industry for professional investors.

NKE $52B
Latticework by MOI Global 1 click

Nike, Part One: The Story

Nike grew from a $1,000 shoe-distribution venture in 1964 into the largest sports brand, using athlete endorsements, product innovation and…

NKE $52B
Latticework by MOI Global 2 clicks

Publications we follow

Every publication on this site, hand-picked.

129 publications

Newsletters 107

YouTube 4

Blogs 17

Seeking Alpha 49 of 227

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

88 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.